Willingness to Pay for COVID-19 Vaccines in Japan

Author:

Yoda Takeshi12ORCID,Iwasaki Nagisa1,Katsuyama Hironobu1ORCID

Affiliation:

1. Department of Public Health, Kawasaki Medical School, Kurashiki 701-0192, Japan

2. Department of Health and Sports Science, Kawasaki University of Medical Welfare, Kurashiki 701-0193, Japan

Abstract

More than 80% of the Japanese population had received the coronavirus disease 2019 (COVID-19) vaccination by the end of April 2023; however, this vaccination rate continues to decline along with the need for booster shots. Further, the vaccines may not permanently be available free of charge. This study conducted a survey to determine the public’s willingness to pay for the COVID-19 vaccine in Japan. Using an internet research panel, the questionnaire collected data on various sociodemographic variables and the respondents’ willingness to pay for COVID-19 vaccines. Descriptive statistics and logistic regression analysis were used to evaluate the respondents’ answers. The results showed that of 1100 respondents, 55.2% would not want to receive the vaccine if it was paid for. A total of 44.8% respondents expressed willingness to pay, with most (170 respondents) willing to pay for 1000–1999 JPY (7.1–14.2 USD). Logistic regression analysis revealed that age, educational status, history of contracting COVID-19, and COVID-19 vaccination frequency were significantly associated with those who were willing to receive the COVID-19 vaccine if it was free (p < 0.05). These findings provide valuable insights for the Japanese government in determining appropriate pricing strategies to promote COVID-19 vaccination effectively.

Publisher

MDPI AG

Subject

Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health

Reference38 articles.

1. Prime Minister’s Office of Japan (2023, February 25). COVID-19 Vaccines, Available online: https://japan.kantei.go.jp/ongoingtopics/vaccine.html.

2. Yoda, T., and Katsuyama, H. (2021). Willingness to Receive COVID-19 Vaccination in Japan. Vaccines, 9.

3. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine;Polack;N. Engl. J. Med.,2020

4. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months;Thomas;N. Engl. J. Med.,2021

5. Oxford-AstraZeneca COVID-19 vaccine efficacy;Knoll;Lancet,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3